Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 17/20 | 0.69 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210549 | 0.90 | CACNA1H (0.65) | CACNA1HGPR119POLB | |
| SCHEMBL8227878 | 0.89 | CACNA1H (0.54) | CACNA1HGPR119POLBNPSR1 | |
| SCHEMBL8209532 | 0.88 | CACNA1H (0.54) | CACNA1HGPR119 | |
| SCHEMBL8217950 | 0.88 | CACNA1H (0.54) | CACNA1HGPR119 | |
| SCHEMBL12876618 | 0.87 | CACNA1H (0.53) | CACNA1HMAPTCNR1NPSR1GPR35 | |
| SCHEMBL8210129 | 0.86 | CACNA1H (0.66) | CACNA1HGPR119POLB | |
| SCHEMBL8212424 | 0.86 | CACNA1H (0.52) | CACNA1HGPR119 | |
| SCHEMBL8202485 | 0.85 | CACNA1H (0.51) | CACNA1HGPR119 | |
| SCHEMBL8225731 | 0.84 | CACNA1H (0.48) | CACNA1HGPR119 | |
| SCHEMBL8228606 | 0.82 | CACNA1H (0.48) | CACNA1HGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066316-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033447-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033447-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | OPRD1, OPRK1, OPRL1 | CACNA1H 1231/4885GPR119 165/4885POLB 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.